Plus therapeutics reports third quarter 2023 financial results and business highlights

New survival data from 15 patients in the phase 2 respect-gbm trial of rhenium ( 186 re) obisbemeda in recurrent glioblastoma (rgbm) will be presented at sno annual meeting on november 17 th ; company will also host a key opinion leader (kol) event following the meeting to discuss the results
PSTV Ratings Summary
PSTV Quant Ranking